Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Pediatr Adolesc Gynecol ; 34(5): 610-616, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33571658

ABSTRACT

OBJECTIVE: To understand whether polycystic ovarian morphology (PCOM) represents a transient phase, and whether an increased stroma could help to characterize the phenotype of the ovary in adolescence. METHODS: Cross-sectional population-based study on high-school students in Cagliari, Italy. The study population consisted of 257 normocyclic non-hyperandrogenic girls selected from a sample of 600 healthy volunteers recruited from 2012 to 2016. Clinical examination, medical history, blood sampling, and pelvic ultrasound (US) were performed. Postmenarchal years and body mass index (BMI) were estimated. Follicle-stimulating hormone (FSH), luteinizing hormone (LH), 17ß estradiol (E2), total testosterone (tT), delta-4-androstenedione (A), and 17-hydroxyprogesterone (17-OHP) were measured. Ovarian volume, follicular number per section (FNPS), and S/A ratio were measured by pelvic US. RESULTS: Following the Rotterdam guidelines for US PCOS diagnosis and setting the normal S/A ratio at ≤0.3, subjects were categorized into 3 groups: (1) normal ovarian morphology (NOM; n = 154, 60%); (2) polycystic ovarian morphology (PCOM) with normal S/A ratio (PCOM-NS; n = 70, 27%); and (3) PCOM with increased S/A ratio (PCOM-IS; n = 33, 13%). The NOM group had more postmenarchal years and a lower LH than both the PCOM groups, and lower A and tT than the PCOM-IS group. The PCOM-NS group had fewer postmenarchal years and lower A than the PCOM-IS group. Interestingly, unlike NOM and PCOM-NS, the prevalence of PCOM-IS remained constant among the 3 phases of postmenarchal age (10% vs 16% vs 15%, P = not significant). CONCLUSION: This study demonstrates that PCOM can be a transient condition, whereas a high S/A ratio is a stable US alteration present from early postmenarchal years.


Subject(s)
Polycystic Ovary Syndrome , Adolescent , Anti-Mullerian Hormone , Cross-Sectional Studies , Female , Humans , Polycystic Ovary Syndrome/diagnostic imaging , Ultrasonography
2.
Gynecol Endocrinol ; 34(5): 394-398, 2018 May.
Article in English | MEDLINE | ID: mdl-29108453

ABSTRACT

Hyperandrogenism is a condition affecting 5-10% of adolescents. The aim of this study was to evaluate the efficacy of very low dose of flutamide in the treatment of hyperandrogenism in adolescence. One hundred and fifty-eight patients, presenting severe acne and/or hirsutism, received 62.5 mg/day of flutamide + ethinylestradiol + gestodene for 18 months. The patients were subjected to assessments of hepatic enzymes levels. Thirty subjects treated with drospirenone + ethinylestradiol represented the control group. After 18 months of treatment, it was obtained a decrease of hirsutism (-39.9%), an almost recovery of acne (98% of patients) with better results of those obtained in control group. Only one case of light hypertransaminasemia was recorded, regressed spontaneously. Very low dose of flutamide was successful and safe and in the treatment of hyperandrogenism in adolescence.


Subject(s)
Acne Vulgaris/drug therapy , Androgen Antagonists/therapeutic use , Flutamide/therapeutic use , Hirsutism/drug therapy , Hyperandrogenism/drug therapy , Adolescent , Androgen Antagonists/administration & dosage , Androstenes/administration & dosage , Androstenes/therapeutic use , Dose-Response Relationship, Drug , Drug Therapy, Combination , Ethinyl Estradiol/administration & dosage , Ethinyl Estradiol/therapeutic use , Female , Flutamide/administration & dosage , Humans , Norpregnenes/administration & dosage , Norpregnenes/therapeutic use , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...